Rocket Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M | $105.4M | $57.9M | $53.3M |
| SG&A Expense | $86.5M | $102.0M | $73.3M | $58.8M | $41.8M | $28.9M | $18.2M | $17.9M |
| Operating Income | $-231.7M | $-273.2M | $-259.7M | $-224.3M | $-167.2M | $-134.3M | $-76.2M | $-71.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | $1.9M | $1.9M | $1.9M | $1.9M | $3.0M | $7.0M | $6.0M | $6.0M |
| Pretax Income | $-223.1M | $-258.7M | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | — | — | — | — | — |
| Net Income | $-223.1M | $-258.7M | $-245.6M | $-221.9M | $-169.1M | $-139.7M | $-77.3M | $-74.5M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 | $-2.52 | $-1.58 | $-1.89 |
| EPS (Diluted) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 | $-2.52 | $-1.58 | $-1.89 |
| Shares Outstanding (Basic) | 111.1M | 94.8M | 84.0M | 68.1M | 63.2M | 55.4M | 49.0M | 45.1M |
| Shares Outstanding (Diluted) | 111.1M | 94.8M | 84.0M | 68.1M | 63.2M | 55.4M | 49.0M | 45.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |